A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.

BMC Cancer · 2008 · PMC2432064 · PMID 18544172

Europe PMC DOI

hedged sentence

0.4720

closest p · 9.4× alpha

0.4720

boldest claim

The sentences

did not reach statistical significancep = 0.472not close (p > 0.1)

Overall survival was better in KRAS -nonmutated (20.8 months [CI 95%, 14.5-NR]) than in KRAS -mutated patients (13.8 months [CI 95%, 11.5-NR]), however this difference did not reach statistical significance (p = 0.472, log-rank test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.